AFP and hepatocellular carcinoma: Furthermore, we found that myosteatosis was associated with poor prognostic factors for survival in sorafenib-treated HCC patients, independent of traditional risk factors, including vascular invasion, extrahepatic metastasis, and AFP levels > 200 ng/mL.